Genscript Biotech (HKG:1548) booked $532.8 million in attributable loss for 2025, compared with a profit of about $2.96 billion in 2024, according to a Hong Kong bourse filing Sunday.
Shares of the life science services company gained over 1% in morning trade Monday.
Loss per share was $0.2458, compared with earnings of $1.3597 in 2024.
Revenue jumped over 61% year on year to $959.5 million, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments